Indian generic drug players unlikely to be affected by Trump attacks

Generic drug industry in India which supplies to the US is unlikely to be affected: Pankaj Patel

The Indian pharma industry, which account for nearly 40 per cent of the generic drugs in the US, is unlikely to come under pressure after US President-elect Donald Trump attacked the pharmaceutical industry for high drug prices and overseas manufacturing, felt industry here. 

Speaking at the sidelines of the Vibrant Gujarat Global Summit, Pankaj Patel, chairman of Federation of Indian Chambers of Commerce and Industry (FICCI) and also chairman and managing director of Cadila Healthcare Ltd said that generic drug industry in India which supplies to the US is unlikely to be affected. His own firm draws around 35-40 per cent